Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

Share this content:
Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma
Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

The overall risk of second primary malignancies (SPMs) is low and should therefore not impact the current therapeutic decision-making process in patients with multiple myeloma, according to a study published in the journal Annals of Oncology.1

Therapeutic advancements have significantly improved clinical outcomes for patients with multiple myeloma, but increased life expectancy has led to concerns about the long-term risk of SPMs. Therefore, a panel of International Myeloma Working Group members sought to review current data on the potential host-, disease-, and treatment-related risk factors associated with the development of SPMs in patients with multiple myeloma and provide practical recommendations to assist clinicians in treatment decision-making.

Investigators found that the risk of SPMs overall in patients with multiple myeloma is low. In addition, that risk is associated with multiple factors and is partially related to the length of patients' survival.

The literature review showed that lenalidomide administered after, or concurrently with, oral melphalan is significantly associated with increased incidence of SPMs. The panel also found associations between lenalidomide maintenance following high-dose melphalan and increased SPM incidence, but to a lesser extent.

Results showed that the risk of multiple myeloma-related death was significantly higher than the risk of death from SPMs in both cases, with lenalidomide possibly providing a survival benefit.

There was no association between lenalidomide plus dexamethasone, or a regimen containing bortezomib and oral melphalan, dexamethasone, or thalidomide, and an increased risk of SPMs.

The findings ultimately suggest that regimens such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to lenalidomide plus melphalan in order to reduce the risk of SPMs in this era of novel agents and improved survival.


1. Musto P, Anderson KC, Attal M, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2016 Nov 17. doi: 10.1093/annonc/mdw606. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs